Latest News - Biogen
Top Corporates Hub
Biogen
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
29.10.2025 03:09
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit
15.10.2025 12:00
BOSTON, October 15, 2025--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that Goldman Sachs (NYSE:GS) is recognizing David H. Donabedian, Ph.D., Newleos’ Founding Chief Executive Officer and Executive Partner at Longwood Fund, as one of the Most Exceptional Entrepreneurs of 2025 at its Builders and Innovators Summit in Healdsburg, California.
Biogen's Comeback: Why The Bulls Are Finally Winning Again
09.10.2025 10:54
Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!
1 Value Stock with Promising Prospects and 2 We Avoid
09.10.2025 04:43
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback
07.10.2025 15:22
Lexeo Therapeutics received positive FDA feedback, enabling faster path to Accelerated Approval for LX2006 in FA cardiomyopathy. Click to read why LXEO is a Buy.
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
07.10.2025 15:20
The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene therapy, antisense oligonucleotides (ASOs), monoclonal antibodies, and small-molecule modulators. According to DataM Intelligence, the Neuromuscular Disease Therapeutics Market Size reached US$ 11.89 billion in 2023, rose to US$ 13.70 billion in 2024, and is projected to reach US$ 45.62 billion by 2033, growing at a CAGR of 14.4% during 2025–2033.
Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
07.10.2025 15:00
The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based treatments, enzyme replacement therapies (ERTs), and targeted biologics. According to DataM Intelligence, the Rare Disease Therapeutics Market Size reached US$ 135.88 billion in 2023, rose to US$ 154.64 billion in 2024, and is projected to reach US$ 495.27 billion by 2033, expanding at a CAGR of 13.8% during 2025–2033.
ImmunityBio: A Small Bet Is Warranted
03.10.2025 13:24
ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX stock now.
Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?
03.10.2025 11:40
Eisai Co., Ltd. and Biogen Inc. recently announced that Australia’s Therapeutic Goods Administration approved LEQEMBI (lecanemab) for use in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, supported by positive Phase 3 Clarity AD trial data. This marks another key regulatory milestone that expands LEQEMBI’s international reach, as new dosing options gain approval in countries including China and the US, potentially making Alzheimer’s treatment more...
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
03.10.2025 08:56
Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.
Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT
02.10.2025 00:16
With significant upside potential, Biogen Inc. (NASDAQ:BIIB) secures a spot on our list of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. Jefferies began covering Biogen Inc. (NASDAQ:BIIB) on September 26 with a Buy rating and a price target of $190. The firm argued that despite the company’s significant strategic and […]
NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing
30.09.2025 10:49
Lecanemab has secured approvals in 50 countries and is under review in 10 others.
Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls
25.09.2025 13:38
Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls
Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim
25.09.2025 12:53
The market is primed for growth, driven by innovations in stem cell therapies, gene editing, and tissue engineering addressing chronic diseases Regenerative Medicine Market Regenerative Medicine Market Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market - Forecasts from 2025 to 2030" has been added to ResearchAndMarkets.com's offering.The global regenerative medicine market is poised for significant expansion, anticipated to grow from USD 25.458 billion in 2025 to USD 60
Biogen Gets EU Nod for First Postpartum Depression Drug
18.09.2025 14:17
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
18.09.2025 12:40
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients living with neurological disorders. CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therape
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe
18.09.2025 12:30
The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past two years.
Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs
18.09.2025 12:07
The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.
Canaccord Genuity Reiterates a Buy on Biogen (BIIB)
16.09.2025 19:58
Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (NASDAQ:BIIB) reported total revenue of $2.6 billion in its fiscal Q2 2025 results, […]
Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?
16.09.2025 12:05
Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone highlights the growing validation of C4 Therapeutics' targeted protein degradation platform and entitles the company to a US$2 million payment once clinical dosing begins. We'll explore how the FDA acceptance of Biogen's IND application for BIIB142...